ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Randomized Trial"

  • Abstract Number: 0989 • ACR Convergence 2020

    Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial

    Eliza Chakravarty1, Tammy Utset2, Diane Kamen3, Gabriel Contreras4, W. Joseph McCune5, Kenneth Kalunian6, Cynthia Aranow7, Megan Clowse8, Elena Massarotti9, Ellen Goldmuntz10, Jessica Springer10, Lynette Keyes-Elstein11, Bill Barry11, Ashley Pinckney11 and Judith James12, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Chicago, Chicago, IN, 3Medical University of South Carolina, Charleston, SC, 4University of Miami Miller School of Medicine, Miami, 5University of Michigan, Ann Arbor, MI, 6University of California San Diego, La Jolla, CA, 7Feinstein Institutes for Medical Research, Manhasset, NY, 8Duke University, Chapel Hill, NC, 9Brigham and Women's hospital, Boston, MA, 10NIH/NIAID, Rockville, MD, 11Rho, Durham, NC, 12Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy for long term treatment of lupus nephritis and other manifestations of SLE.  However, it is associated…
  • Abstract Number: 1843 • ACR Convergence 2020

    Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids

    Ellen M Ginzler1, Joshua Kaplan2, Laura Lisk3, Ray Federico4, Neil Solomons5 and Robert Huizinga5, 1SUNY Downstate Health Sciences University, Brooklyn, 2Rutgers University, New Brunswick, NJ, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 4Aurinia Pharmaceuticals, Inc., Victoria, Canada, 5Aurinia Pharmaceuticals, Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…
  • Abstract Number: 0675 • ACR Convergence 2020

    AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers

    Zancong Shen1, Elizabeth Polvent2, Vijay Hingorani2, Andrea Clouser-Roche2, Chris Mikelatis2, Rongzi Yan2, Shunqi Yan2 and Li-Tain Yeh2, 1Arthrosi therapeutics, Laguna Hills, CA, 2Arthrosi Therapeutics Inc, Laguna Hills, CA

    Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. AR882 exhibited linear…
  • Abstract Number: 1146 • ACR Convergence 2020

    Pilot Study of an Internet-Based Pain Coping Skills Training Program for Patients with Systemic Lupus Erythematosus

    Kelli Allen1, Tyler Beuchamp2, Rebecca Cleveland3, Kimberlea Grimm1, David Hu1, Katie Huffman1, Frances Keefe4, Julie Norfleet1, Christine Rini5, Andres Santana1, Shruti Saxena Beem6 and Saira Sheikh7, 1University of North Carolina at Chapel Hill, Chapel HIll, NC, 2Medical College of Georgia, Augusta, GA, 3University of North Carolina, Chapel Hill, NC, 4Duke University Medical Center, Durham, NC, 5Northwestern University, Chicago, IL, 6University of North Carolina at Chapel Hill, Chapel Hill, 7University of North Carolina Thurston Arthritis Research Center, Chapel Hill

    Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have increased symptoms of fatigue, chronic pain, depression and anxiety, which are associated with negative impacts on quality…
  • Abstract Number: 2001 • ACR Convergence 2020

    Adverse Effects of Low Dose Methotrexate: Adjudicated Hematologic Outcomes in a Large Randomized Double-blind Placebo-controlled Trial

    Kathleen Vanni1, Nancy Berliner1, Nina Paynter2, Robert Glynn2, Jean MacFadyen1, Joshua Colls1, Fengxin Lu1, Chang Xu2, Paul Ridker1 and Daniel H Solomon1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston

    Background/Purpose: Low dose methotrexate (LD-MTX), a cornerstone in the treatment of rheumatoid arthritis, is associated with a moderately increased risk of anemia and leukopenia, but…
  • Abstract Number: 0690 • ACR Convergence 2020

    AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate in Patients with Gout in a Phase 2a Study

    Li-Tain Yeh1, Elizabeth Polvent1, Zancong Shen2, Vijay Hingorani1, Andrea Clouser-Roche1, Chris Mikelatis1, Shunqi Yan1 and Rongzi Yan1, 1Arthrosi Therapeutics Inc, Laguna Hills, CA, 2Arthrosi therapeutics, Laguna Hills, CA

    Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. Phase 1 single…
  • Abstract Number: 1211 • ACR Convergence 2020

    Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies

    Christina Charles-Schoeman1, Jon Giles2, Nancy Lane3, Ernest Choy4, Heidi Camp5, Yanna Song6, Samuel Anyanwu5 and Iain McInnes7, 1University of California, Los Angeles, Los Angeles, CA, 2Columbia University, New York, NY, 3University of California, Davis, Sacramento, CA, 4CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 5AbbVie Inc., North Chicago, IL, 6AbbVie Inc., North Chicago,, IL, 7Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to have greater selectivity for JAK1 vs JAK2, JAK3, and tyrosine kinase 2, and…
  • Abstract Number: 2009 • ACR Convergence 2020

    Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study

    Linda Hartman1, Linda Rasch2, Samina Turk3, Marieke ter Wee1, Pit Kerstens4, Conny van der Laken5, Mike Nurmohamed6, Dirkjan van Schaardenburg7, Lilian van Tuyl8, Alexandre Voskuyl1, Maarten Boers7 and Willem Lems1, 1Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, 2Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, 3Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands, 4Westfriesgasthuis, Hoorn, Netherlands, 5Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, 6Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, 7Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, 8Nivel, Utrecht, Netherlands

    Background/Purpose: EULAR guidelines advise to start with methotrexate (MTX) for early rheumatoid arthritis (RA), either alone or combined with prednisolone. Since this strategy is not…
  • Abstract Number: 0799 • ACR Convergence 2020

    Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD

    Renske Hebing1, Wouter Bos1, Mike Nurmohamed2 and Bart van den Bemt3, 1Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, 3Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. Electronic Monitoring Feedback (EMF) to improve adherence has…
  • Abstract Number: 1213 • ACR Convergence 2020

    Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis

    Roy Fleischmann1, Jingyu Liu2, Julie Zhu2, Oscar Segurado3 and Daniel Furst*4, 1Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 2Mallinckrodt Pharmaceuticals, Bedminster, NJ, 3SSI Strategy, San Jose, CA, 4Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA

    Background/Purpose: Assessment of disease activity in RA with validated measures, such as the Disease Activity Score with 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)…
  • Abstract Number: 2010 • ACR Convergence 2020

    Stable versus Tapered and Withdrawn Treatment with Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Remission: A Randomized, Open-Label, Phase 4, Non-Inferiority Trial

    Siri Lillegraven1, Nina Paulshus Sundlisæter1, Anna-Birgitte Aga1, Joseph Sexton1, Inge C. Olsen2, Åse Lexberg3, Tor Magne Madland4, Hallvard Fremstad5, Christian Høili6, Gunnstein Bakland7, Cristina Spada8, Hilde Haukeland9, Inger Myrnes Hansen10, Ellen Moholt1, Till Uhlig1, Daniel H. Solomon11, Désirée van der Heijde12, Tore K. Kvien1 and Espen A. Haavardsholm1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3Vestre Viken HF, Drammen, Norway, 4Haukeland University Hospital, Bergen, Norway, 5Ålesund Hospital, Ålesund, Norway, 6Hospital Øsftfold HF, Moss, Norway, 7University Hospital of North Norway, Tromsø, Norway, 8Revmatismesykehuset, Lillehammeer, Norway, 9Martina Hansens Hospital, Bærum, Norway, 10Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, 11Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 12Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Remission is the preferred treatment target in rheumatoid arthritis (RA), and many patients require biologic disease-modifying antirheumatic drugs (DMARDs) to reach this state. It…
  • Abstract Number: 0865 • ACR Convergence 2020

    Efficacy and Safety of Evobrutinib (M2951) in Adult Patients with Systemic Lupus Erythematosus Who Received Standard of Care Therapy: A Phase II, Randomized, Double-blind, Placebo-controlled Dose Ranging Study

    Daniel J Wallace1, Thomas Dörner2, David Pisetsky3, F Jorge Sanchez-Guerrero4, Amy Kao5, Dana Parsons-Rich5, Anand Patel6, Yulia Zima5, Claire Le Bolay7, Karthinathan Thangavelu6 and Maria Dall'Era8, 1Cedars-Sinai Medical Center, Beverly Hills, CA, 2DRFZ and Charité University Hospitals, Berlin, Germany, 3Duke University Medical Center, Durham, NC, 4University Health Network/Sinai Health system, Toronto, ON, Canada, 5EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 6EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, 7Merck KGaA, Darmstadt, Germany, 8Division of Rheumatology, University of California, San Francisco, CA

    Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in signalling pathways known to be important to the pathogenesis of systemic lupus erythematosus (SLE). Evobrutinib is a…
  • Abstract Number: 1344 • ACR Convergence 2020

    Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced

    Christopher Ritchlin1, Philip Helliwell2, Wolf-Henning Boehncke3, Elizabeth Hsia4, Alexa Kollmeier5, Ramanand Subramanian6, Xie Xu7, Shihong Sheng6, Yusang Jiang6, Bei Zhou6 and Atul Deodhar8, 1Department of Medicine, University of Rochester Medical Center, Rochester, NY, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Geneva University Hospitals, Geneva, Switzerland, 4Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, 5Janssen Research & Development, LLC, La Jolla, CA, 6Janssen Research & Development, LLC, Spring House, PA, 7Janssen Research & Development, LLC, San Marcos, CA, 8Oregon Health & Science University, Portland, OR

    Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis (PsO). At Week 24 of the…
  • Abstract Number: 2012 • ACR Convergence 2020

    A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate

    Charles Peterfy1, Maya Buch2, Ernest Choy3, Georg Schett4, Dana Parsons-Rich5, Anand Patel6, Yulia Zima5, Claire Le Bolay7 and Mark Genovese8, 1Spire Sciences, Inc., Boca Raton, FL, 2Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, 3CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 4Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 5EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 6EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, 7Merck KGaA, Darmstadt, Germany, 8Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA

    Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in multiple signalling pathways potentially implicated in rheumatoid arthritis (RA). Evobrutinib is a highly selective, oral BTK inhibitor.…
  • Abstract Number: 0875 • ACR Convergence 2020

    Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study

    Iain McInnes1, Hector Chinoy2, Darren Asquith3, Abigail White3 and Corine Gaillez4, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2The University of Manchester, Manchester, United Kingdom, 3Novartis Pharmaceuticals UK Ltd., London, United Kingdom, 4Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology